- Home
- AKRO vs SUPN Comparison
AKRO vs SUPN Comparison
Compare AKRO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- SUPN
- Stock Information
- Founded
- AKRO 2017
- SUPN 2005
- Country
- AKRO United States
- SUPN United States
- Employees
- AKRO N/A
- SUPN N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- AKRO Health Care
- SUPN Health Care
- Exchange
- AKRO Nasdaq
- SUPN Nasdaq
- Market Cap
- AKRO 3.9B
- SUPN 1.9B
- IPO Year
- AKRO 2019
- SUPN 2012
- Fundamental
- Price
- AKRO $51.77
- SUPN $31.70
- Analyst Decision
- AKRO Strong Buy
- SUPN Hold
- Analyst Count
- AKRO 6
- SUPN 2
- Target Price
- AKRO $82.50
- SUPN $36.00
- AVG Volume (30 Days)
- AKRO 1.7M
- SUPN 685.5K
- Earning Date
- AKRO 08-08-2025
- SUPN 08-05-2025
- Dividend Yield
- AKRO N/A
- SUPN N/A
- EPS Growth
- AKRO N/A
- SUPN N/A
- EPS
- AKRO N/A
- SUPN 1.11
- Revenue
- AKRO N/A
- SUPN $667,997,000.00
- Revenue This Year
- AKRO N/A
- SUPN N/A
- Revenue Next Year
- AKRO N/A
- SUPN $12.02
- P/E Ratio
- AKRO N/A
- SUPN $28.89
- Revenue Growth
- AKRO N/A
- SUPN 11.82
- 52 Week Low
- AKRO $21.02
- SUPN $25.55
- 52 Week High
- AKRO $58.40
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- AKRO 49.14
- SUPN 48.95
- Support Level
- AKRO $51.08
- SUPN $30.93
- Resistance Level
- AKRO $57.35
- SUPN $32.78
- Average True Range (ATR)
- AKRO 2.21
- SUPN 1.00
- MACD
- AKRO -0.81
- SUPN -0.03
- Stochastic Oscillator
- AKRO 11.08
- SUPN 46.56
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.